Drug intelligence / Profile preview

PBI-204

Development stage: Preclinical
Lead developer: Protheragen
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

PBI-204 is a preclinical-stage monoclonal antibody developed by Protheragen for the treatment of sepsis. It specifically targets adrenomedullin (ADM), a regulatory peptide that plays a critical role in vascular homeostasis. In the context of sepsis, elevated levels of adrenomedullin contribute to pathological vasodilation and endothelial barrier breakdown, leading to capillary leak and septic shock. PBI-204 is designed to modulate or neutralize these effects to restore vascular integrity and improve hemodynamic stability in patients with severe systemic infections.

Targets

ADM (Adrenomedullin)

Beyond the preview

Go deeper on PBI-204.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PBI-204.

Explore the full profile